DRIO vs LLY vs HIMS vs CVS vs UNH

For growth investors, Hims & Hers Health, Inc.

(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -17. 3% for DarioHealth Corp. (DRIO). DarioHealth Corp. (DRIO) offers the better valuation at 5. 6x trailing P/E, making it the more compelling value choice. Analysts rate DarioHealth Corp. (DRIO) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, DarioHealth Corp.

(DRIO) is the cheapest at 5. 6x versus CVS Health Corporation at 70. 7x. On forward P/E, CVS Health Corporation is actually cheaper at 13. 3x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +413.

8%, compared to -98. 4% for DarioHealth Corp. (DRIO). Over 10 years, the gap is even starker: LLY returned +1450% versus DRIO's -99. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), CVS Health Corporation (CVS) is the lower-risk stock at 0.

19β versus Hims & Hers Health, Inc. 's 2. 53β — meaning HIMS is approximately 1255% more volatile than CVS relative to the S&P 500. On balance sheet safety, DarioHealth Corp. (DRIO) carries a lower debt/equity ratio of 47% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Hims & Hers Health, Inc.

(HIMS) is pulling ahead at 59. 0% versus -17. 3% for DarioHealth Corp. (DRIO). On earnings-per-share growth, the picture is similar: DarioHealth Corp. grew EPS 267. 6% year-over-year, compared to -62. 0% for CVS Health Corporation. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Eli Lilly and Company (LLY) is the more profitable company, earning 31.

7% net margin versus -186. 6% for DarioHealth Corp. — meaning it keeps 31. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 45. 6% versus -163. 9% for DRIO. At the gross margin level — before operating expenses — LLY leads at 83. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, CVS Health Corporation (CVS) trades at 13.

3x forward P/E versus 30. 0x for Eli Lilly and Company — 16. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DRIO: 80. 4% to $12. 50.

In this comparison, CVS (2.

7% yield), UNH (2. 2% yield), LLY (0. 5% yield) pay a dividend. DRIO, HIMS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

52), 0. 5% yield, +1450% 10Y return). Hims & Hers Health, Inc. (HIMS) carries a higher beta of 2. 53 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LLY: +1450%, HIMS: +261. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: DRIO is a small-cap deep-value stock; LLY is a mega-cap high-growth stock; HIMS is a small-cap high-growth stock; CVS is a mid-cap quality compounder stock; UNH is a large-cap quality compounder stock. LLY, CVS, UNH pay a dividend while DRIO, HIMS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.